{
    "clinical_study": {
        "@rank": "132812", 
        "arm_group": {
            "arm_group_label": "BI 201335", 
            "arm_group_type": "Experimental", 
            "description": "BI 201335 two single oral doses, separated by 14 days washout period"
        }, 
        "brief_summary": {
            "textblock": "This trial was intended to investigate the pharmacokinetics, safety and tolerability of BI\n      201335 NA soft-gel capsules in patients with compensated liver cirrhosis, i.e. grade A\n      according to Child-Pugh classification (< 7 points)."
        }, 
        "brief_title": "Open Label Single Dose Phase I Trial of BI 201335 to Study Pharmacokinetics and Safety in Patients With Compensated Liver Cirrhosis", 
        "completion_date": {
            "#text": "October 2008", 
            "@type": "Actual"
        }, 
        "condition": [
            "Hepatitis C", 
            "Liver Cirrhosis"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Hepatitis", 
                "Hepatitis A", 
                "Hepatitis C", 
                "Liver Cirrhosis", 
                "Fibrosis"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion criteria:\n\n          1. Patients with liver cirrhosis, that is histologically proven in a previous liver\n             biopsy; possible aetiologies are: cured HCV infection, former alcohol abuse, genetic\n             haemochromatosis, non-alcoholic steatohepatitis or others.\n\n          2. Compensated liver disease, as indicated by Prothrombin time or INR prolonged to <1.7\n             x ULN, serum bilirubin < 2 mg/dl, albumin > 3.5 g/dl, no ascites or encephalopathy\n             (Child-Pugh grade A, score < 7)\n\n          3. Age 18 years or older\n\n          4. Male patients, or female with documented hysterectomy, ovariectomy or tubal ligation\n             OR menopausal female with last menstrual period at least 12 months prior to screening\n             OR female of childbearing potential with a negative serum pregnancy test at screening\n             and day 1 and willing to ensure consistent and correct contraception\n\n          5. Written informed consent prior to study enrolment which must be consistent with\n             international conference on harmonisation \u00bf good clinical practice (ICH-GCP) and\n             local legislation.\n\n        Exclusion criteria:\n\n          1. Serological evidence of active HBV, HCV or HIV infection (i.e. seropositivity for HBs\n             antigen, anti-HIV-1 or -2 antibodies; if anti-HCV antibody positive, patients must\n             have documented negative HCV RNA for at least 12 months)\n\n          2. Usage of any drug within 7 days or 5 halftimes, whichever is longer, prior to\n             treatment; or the planned usage of a drug during the course of the current study\n\n          3. Usage of any investigational drug within 30 days prior to treatment; or the planned\n             usage of an investigational drug during the course of the current study\n\n          4. Decompensated liver disease within past 12 months, as indicated by variceal bleeding,\n             ascites, encephalopathy, Prothrombin time or INR prolonged to > 1,7 x ULN, serum\n             bilirubin > 2 mg/dl or albumin < 3,5 g/dl (i.e. Child-Pugh grade B)\n\n          5. ALT or AST levels > 5xULN, Alkaline Phosphatase > 2xULN\n\n          6. Liver cirrhosis due to primary or secondary biliary cirrhosis, sclerosing\n             cholangitis, vanishing bile duct disease\n\n          7. History of alcohol abuse within the past 3 months\n\n          8. Known hypersensitivity to any content of the study drug\n\n          9. Pregnant or breast feeding females\n\n         10. Females of childbearing potential who are not willing to ensure consistent and\n             correct use of condoms and at least one additional medically accepted method of\n             contraception (diaphragm with spermicidal substance, cervical caps) or who are\n             unwilling to comply to complete abstinence, from the date of screening until 6 months\n             after the last dose of study drug\n\n         11. AFP value > 100 ng/ml; if AFP is > 20 and <= 100 ng/ml, patients can be included if\n             liver cancer is excluded by two congruent imaging studies (i.e. ultrasound plus CT\n             scan or MRI)\n\n         12. Evidence of chronic kidney failure (i.e. serum creatinine > ULN)\n\n         13. Haemoglobinopathy (e.g., thalassaemia major or sickle cell anaemia)\n\n         14. Concomitant intercurrent illnesses including, but not limited to, ongoing or active\n             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac\n             arrhythmia, or psychiatric illness or social situation that would limit compliance\n             with trial requirement or which are considered relevant for the evaluation of the\n             pharmacokinetic parameters or safety of the trial drug.\n\n         15. Active or suspected malignancy or history of malignancy within the last 2 years (with\n             the exception of appropriately treated basal cell carcinoma or in situ carcinoma of\n             the uterine cervix)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "2", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "July 25, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01909778", 
            "org_study_id": "1220.15", 
            "secondary_id": "2007-007776-42"
        }, 
        "intervention": {
            "arm_group_label": "BI 201335", 
            "description": "single oral doses", 
            "intervention_name": "BI 201335", 
            "intervention_type": "Drug"
        }, 
        "lastchanged_date": "July 26, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Mainz", 
                    "country": "Germany"
                }, 
                "name": "1220.15.49006 Boehringer Ingelheim Investigational Site"
            }
        }, 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_arms": "1", 
        "official_title": "An Open Label Single Dose Phase I Trial of 120 mg and 240 mg BI 201335 Soft Gel Capsules to Study Pharmacokinetic Properties and Safety in Patients With Compensated Liver Cirrhosis in Historical Comparison With 1220.2", 
        "overall_official": {
            "affiliation": "Boehringer Ingelheim", 
            "last_name": "Boehringer Ingelheim", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": [
                "Germany: Federal Institute for Drugs and Medical Devices", 
                "United States: Food and Drug Administration"
            ]
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "October 2008", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "AUC 0-8 (Area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity)", 
                "safety_issue": "No", 
                "time_frame": "1-24 days"
            }, 
            {
                "measure": "Cmax (Maximum plasma concentration)", 
                "safety_issue": "No", 
                "time_frame": "1-24 days"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01909778"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "tmax (Time at which the maximum plasma concentration occurs)", 
                "safety_issue": "No", 
                "time_frame": "1-24 days"
            }, 
            {
                "measure": "t1/2 (Elimination half-life)", 
                "safety_issue": "No", 
                "time_frame": "1-24 days"
            }, 
            {
                "measure": "CL/F (Apparent clearance of the analyte in plasma following extravascular administration)", 
                "safety_issue": "No", 
                "time_frame": "1-24 days"
            }, 
            {
                "measure": "VZ/F (Apparent volume of distribution during the terminal phase following an extravascular dose)", 
                "safety_issue": "No", 
                "time_frame": "1-24 days"
            }, 
            {
                "measure": "MRTpo (Mean residence time of the analyte in the body after oral administration)", 
                "safety_issue": "No", 
                "time_frame": "1-24 days"
            }, 
            {
                "measure": "Vital signs", 
                "safety_issue": "No", 
                "time_frame": "1-24 days"
            }, 
            {
                "measure": "ECG (Electrocardiogram)", 
                "safety_issue": "No", 
                "time_frame": "1-24 days"
            }, 
            {
                "measure": "Clinical laboratory testing (haematology, clinical chemistry, urinalysis)", 
                "safety_issue": "No", 
                "time_frame": "1-24 days"
            }, 
            {
                "measure": "Adverse events", 
                "safety_issue": "No", 
                "time_frame": "1-24 days"
            }, 
            {
                "measure": "Assessment of tolerability by investigator", 
                "safety_issue": "No", 
                "time_frame": "1-24 days"
            }, 
            {
                "measure": "AUC0-tz (Area under the concentration-time curve over the time interval from 0 to the last quantifiable plasma concentration)", 
                "safety_issue": "No", 
                "time_frame": "1-24 days"
            }
        ], 
        "source": "Boehringer Ingelheim", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Boehringer Ingelheim", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2008", 
        "study_design": "Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "July 2013"
    }
}